|
|
 |
|
Viewing report
|
|
|
|
Opportunities in Emerging Markets - Latin America, Brazil, and Mexico
Decision Resources, Inc, June 2011
The countries of Latin America and the Caribbean are all categorized as emerging and developing economies. Pharmaceutical companies mostly prioritize Brazil, Russia, India, China, Mexico, and Turkey (BRIC-MT) for their emerging market strategies, but two of these markets are in Latin America. In addition, other small and midsize Latin American markets offer significant opportunities to pharma companies looking to expand in emerging markets. In this report, we investigate the emerging markets of Latin America and compare these markets with the advanced economies of Japan and the United States and the other emerging BRIC-MT economies. We explore the differences and similarities among these diverse markets and discuss strategies and opportunities for pharmaceutical companies in Latin America.
Questions answered:
- The International Monetary Fund forecasts significant growth in many Latin American economies for 2011. Which Latin America economies will have the fastest growth in 2011 over 2010? How does that compare with expected growth in other BRIC-MT economies and advanced economies?
- The World Economic Forum (WEF) assesses the strengths and weaknesses of countries around the world and issues an annual global competitiveness index (GCI) that ranks country economies. How do the emerging markets of Latin America compare with those of the other BRIC-MT countries? How do they compare with the advanced economies of Japan and the United States?
- In April 2011, the Brazilian government announced a program to provide free drugs for certain diseases, and the Mexican government reported that the proportion of the population paying out of pocket for healthcare had fallen 10% in ten years. What is the Health Has No Price program in Brazil? Who pays for health expenditures in Latin American countries? What percentage of privately paid health expenditures is paid by private health insurance in Latin American countries?
- AstraZeneca’s position is that there is a lot more to emerging markets than just BRIC-MT. What approach is this company espousing? Which countries is it targeting? What level of operating margins has AstraZeneca obtained in emerging markets?
- Sanofi CEO Christopher Viehbacher says it is dangerous to talk about emerging markets in a generic way. Why? What competitive advantages does Sanofi have in emerging markets? What key strategies does Viehbacher promote for operating in these markets?
- Teva Americas CEO William Marth says his company still needs to work on growing its international business. How does Teva view Latin American acquisition targets? Why is Teva taking a measured approach to new acquisitions?
- In an analysis of 15 parameters tracked by the World Economic Forum (WEF), certain Latin American countries often rank among the bottom five countries. Which countries rank low on which parameters? What are the top problems for doing business in those countries? Which countries consistently rank high on the WEF parameters?
Scope:
Geographies: Latin America; Mexico; Central American countries of Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama; South American countries of Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Uruguay, and Venezuela; advanced economies of Japan and the United States; emerging markets of Brazil, Russia, India, China, Mexico, Turkey (BRIC-MT).
Emerging versus advanced market comparisons: Global competitive index, population, gross domestic product (GDP), GDP per capita, health expenditures, infant mortality, life expectancy, correlation of worker productivity to pay, labor force female-to-male ratio, quality of math and science education, prevalence of trade barriers, number of clinical trials, intellectual property protection, foreign ownership of companies, favoritism in decisions by government officials, utility patents, intensity of local competition, extent of market dominance, financial services, local equity markets, venture capital, size of pharmaceutical market.
Pharmaceutical industry: Recent deals, clinical trials, multinational corporations (MNCs), domestic companies, contract research organizations (CROs), outsourcing, offshoring, density of physicians and pharmaceutical personnel, healthcare, market size, similares, generics, bolt-on acquisitions, patent protection, mergers and acquisitions (M&As), market portfolios, innovative brands, market share, branded generics, operating margins, local management, manufacturing, investment priorities, human resources machine, production network, tail products.
Expert insight: Peter Wittner, principal, Interpharm Consultancy, provides insight on recent news and events relating to the healthcare and pharmaceutical industries in Brazil and Mexico. Mr. Wittner specializes in generics strategies. Previously, he worked at Ranbaxy (U.K.), H.N. Norton (subsequently part of Ivax), Evans Medical, A.H. Robins, and Koppel & Co. in general management, business development, and sales and marketing.
Exhibits: 27 data-rich tables and figures.
|
|
|
|
